Neuromod’s Tinnitus Treatment Device Expands Availability in Spain
Lenire’s Spanish launch began in Barcelona. This latest expansion brings the number of clinics in Spain providing Lenire to four.
Lenire’s Spanish launch began in Barcelona. This latest expansion brings the number of clinics in Spain providing Lenire to four.
Neosensory’s advanced hearing technology has been approved for Department of Veterans Affairs clinic locations across the country.
Participants who used Neosensory’s Duo solution daily for eight weeks reported clinically significant reduction in their tinnitus severity. A decrease in the Tinnitus Functional Index score of greater than 13 points indicates a reduction in tinnitus symptoms that is clinically significant and impactful on one’s quality of daily life.
Neuromod Devices Ltd has reached an agreement with Specialklinikken Borgå ApS, a Danish provider of private care for tinnitus, to make its Lenire device available in Denmark.
Specialist tinnitus service, Ótologie Tinnitus Care is offering free assessments to people living with tinnitus to mark its sponsorship of the British Tinnitus Association’s Tinnitus Week, which runs from February 7-13, 2022.
An international team, including a University of Minnesota professor, has published a second large clinical trial for a novel neuromodulation device, Lenire, that could reduce symptoms for millions worldwide with tinnitus, commonly described as “ringing in the ears.” Researchers published the results of the Treatment Evaluation of Neuromodulation for Tinnitus – Stage A2 (TENT-A2) clinical trial in “Nature – Scientific Reports.” An article detailing the research appears on the University of Minnesota website.